Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction

Liangpeng Li1, Xiaodi Wang1, Wen Chen1

  • 1Department of Thoracic and Cardiovascular Surgery, Nanjing Hospital Affiliated to Nanjing Medical University, Changle Road 68, Nanjing, 210006, Jiangsu, People's Republic of China.

Insights

Caspase activation and recruitment domain 3 (CARD3) exacerbates cardiac remodeling after myocardial infarction (MI). Inhibiting CARD3 protects the heart, reducing infarct size and improving function by modulating NF-κB and p38 signaling.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cell Death Research

Background:

  • Caspase activation and recruitment domain 3 (CARD3) is a kinase involved in apoptosis and tissue development.
  • The role of CARD3 in myocardial infarction (MI) and cardiac remodeling is not well understood.

Purpose of the Study:

  • To investigate the functional significance of CARD3 in cardiac remodeling post-MI.
  • To elucidate the underlying molecular mechanisms of CARD3's effects on the heart after infarction.

Main Methods:

  • Analysis of CARD3 expression in human and mouse post-MI hearts.
  • Generation and MI induction in CARD3-knockout (KO) and CARD3-overexpressing mice.
  • Assessment of cardiac function, infarct size, apoptosis, inflammation, hypertrophy, and fibrosis.
  • In vitro studies using neonatal rat cardiomyocytes exposed to hypoxia.

Main Results:

  • CARD3 expression is upregulated in failing hearts post-MI.
  • CARD3-KO mice showed reduced infarct size, improved survival, preserved left ventricle (LV) function, less cardiomyocyte apoptosis, and attenuated LV remodeling compared to wild-type mice.
  • CARD3 overexpression led to opposite effects, worsening MI outcomes.
  • CARD3-mediated detrimental effects involved activation of NF-κB and p38 signaling pathways.

Conclusions:

  • CARD3 is a novel positive modulator of cardiac remodeling after MI.
  • CARD3 promotes adverse ventricular remodeling through NF-κB and p38 signaling activation.
  • Targeting CARD3 may offer a therapeutic strategy for treating heart failure post-MI.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
718
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
765
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
641
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
816
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
321